{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:52:12Z","timestamp":1772945532072,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020953","name":"Taiwan Centers for Disease Control","doi-asserted-by":"publisher","award":["MOHW109-CDC-C-315-112105"],"award-info":[{"award-number":["MOHW109-CDC-C-315-112105"]}],"id":[{"id":"10.13039\/100020953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jmii.2025.08.012","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T21:08:09Z","timestamp":1755810489000},"page":"244-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitigating unfavourable treatment outcomes and acquired rifampicin resistance in isoniazid-resistant tuberculosis: the role of fluoroquinolone"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1001-7562","authenticated-orcid":false,"given":"Pin-Hui","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-1868","authenticated-orcid":false,"given":"Pei-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Wei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Fang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Yun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-2490","authenticated-orcid":false,"given":"Chen-Yuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2025.08.012_bib1","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib2","first-page":"1","volume":"vol. 20","year":"2018"},{"key":"10.1016\/j.jmii.2025.08.012_bib3","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American thoracic society\/centers for disease control and prevention\/infectious diseases society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2025.08.012_bib5","first-page":"1","article-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","volume":"11","year":"2014","journal-title":"World Health Organization Document"},{"issue":"4","key":"10.1016\/j.jmii.2025.08.012_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01494-2019","article-title":"Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?","volume":"54","author":"Diel","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2025.08.012_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2025.08.012_bib10","first-page":"1","article-title":"Supplement to the WHO treatment guidelines for drug-resistant tuberculosis","volume":"7","year":"2018","journal-title":"World Health Organization Document"},{"issue":"4","key":"10.1016\/j.jmii.2025.08.012_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00982-2019","article-title":"Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance","volume":"54","author":"Stagg","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2025.08.012_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1513\/AnnalsATS.201702-147OC","article-title":"Isoniazid monoresistance and rate of culture conversion among patients in the state of Georgia with confirmed tuberculosis, 2009-2014","volume":"15","author":"Salindri","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jmii.2025.08.012_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2458-11-915","article-title":"Completeness and timeliness of tuberculosis notification in Taiwan","volume":"11","author":"Lo","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jmii.2025.08.012_bib14","article-title":"Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2025.08.012_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciy066","article-title":"Treatment outcomes of multidrug-resistant tuberculosis in taiwan: tackling loss to follow-up","volume":"67","author":"Yu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"key":"10.1016\/j.jmii.2025.08.012_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.5588\/ijtld.11.0637","article-title":"Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009","volume":"16","author":"Gegia","year":"2012","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.01377-15","article-title":"Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis","volume":"60","author":"Lee","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2025.08.012_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229691","article-title":"Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017","volume":"15","author":"Edwards","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2025.08.012_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3201\/eid2403.171362","article-title":"Acquired resistance to antituberculosis drugs in England, Wales, and northern Ireland, 2000-2015","volume":"24","author":"Loutet","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac037","article-title":"Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings","volume":"4","author":"Van Deun","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jmii.2025.08.012_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.5588\/ijtld.21.0701","article-title":"Factors influencing treatment outcomes in patients with isoniazid-resistant pulmonary TB","volume":"26","author":"Velayutham","year":"2022","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jmii.2025.08.012_bib24","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2025.08.012_bib25","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cmi.2016.11.015","article-title":"True rifampicin resistance missed by the MGIT: prevalence of this pheno\/genotype in the UK and Ireland after 18 month surveillance","volume":"23","author":"Gonzalo","year":"2017","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118225001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:12:01Z","timestamp":1772892721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118225001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1684118225001604"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2025.08.012","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigating unfavourable treatment outcomes and acquired rifampicin resistance in isoniazid-resistant tuberculosis: the role of fluoroquinolone","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2025.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}